Free Trial

Oramed Pharmaceuticals (ORMP) Earnings Date, Estimates & Call Transcripts

Oramed Pharmaceuticals logo
$2.32
-0.06 (-2.52%)
(As of 11/1/2024 ET)

Oramed Pharmaceuticals Latest Earnings Summary

Upcoming Q3
Earnings Date
Nov. 14Estimated
Actual EPS
(Aug. 14)
$0.22 Beat By $0.21
Consensus EPS
(Aug. 14)
$0.01

Oramed Pharmaceuticals announced Q2 2024 earnings on August 14, 2024, reporting an EPS of $0.22, which beat the consensus estimate of $0.01 by $0.21. With a trailing EPS of $0.51 and a P/E Ratio of 4.55, Oramed Pharmaceuticals' earnings are expected to decrease next year, from $0.24 to ($0.08) per share.

ORMP Upcoming Earnings

Oramed Pharmaceuticals' next earnings date is estimated for Thursday, November 14, 2024, based off prior year's reporting schedules.

Get Oramed Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ORMP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ORMP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Oramed Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241$0.02$0.02$0.02
Q2 20242-$0.02$0.04$0.01
Q3 20242-$0.02$0.03$0.01
Q4 20242-$0.07-$0.03-$0.05
FY 20247-$0.09$0.06-$0.02
Q1 20251-$0.05-$0.05-$0.05
Q2 20251-$0.06-$0.06-$0.06
Q3 20251-$0.07-$0.07-$0.07
Q4 20251-$0.08-$0.08-$0.08
FY 20254($0.26)($0.26)($0.26)

Oramed Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
11/14/2024
(Estimated)
------- 
8/14/2024Q2 2024$0.01$0.22+$0.21$0.22--
5/9/2024Q1 2024$0.02$0.04+$0.02$0.04--
3/6/2024Q4 2023-$0.12-$0.08+$0.04-$0.49--
11/9/2023Q3 2023-$0.09-$0.08+$0.01-$0.08--
8/10/2023Q2 2023-$0.11-$0.03+$0.08-$0.03$0.70M$0.67M
5/11/2023Q1 2023-$0.23-$0.08+$0.15-$0.08$0.75M$0.67M
3/6/2023Q4 2022-$0.22-$0.22--$0.22$0.75M$0.68M
11/10/2022Q3 2022-$0.26-$0.18+$0.08-$0.18$0.70M$0.68M

Oramed Pharmaceuticals Earnings - Frequently Asked Questions

Oramed Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on ORMP's earnings history.

In the previous quarter, Oramed Pharmaceuticals (NASDAQ:ORMP) reported $0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $0.01 by $0.21. Learn more on analysts' earnings estimate vs. ORMP's actual earnings.

Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded annual revenue of $1.34 million.

Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded net income of $5.53 million. ORMP has generated $0.51 earnings per share over the last four quarters.

Oramed Pharmaceuticals (NASDAQ:ORMP) has a trailing price-to-earnings ratio of 4.55 and a forward price-to-earnings ratio of 9.67.

Oramed Pharmaceuticals's earnings are expected to decrease from $0.24 per share to ($0.08) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:ORMP) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners